Tonix Pharmaceuticals Holding Corp.
TNXP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $3,290 | $1,998 | $2,429 | $2,582 |
| % Growth | 64.7% | -17.7% | -5.9% | – |
| Cost of Goods Sold | $1,367 | $3,272 | $943 | $1,183 |
| Gross Profit | $1,923 | -$1,274 | $1,486 | $1,399 |
| % Margin | 58.4% | -63.8% | 61.2% | 54.2% |
| R&D Expenses | $9,289 | $10,820 | $7,436 | $8,297 |
| G&A Expenses | $0 | $0 | $10,104 | $3,400 |
| SG&A Expenses | $0 | $0 | $10,104 | $15,582 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $12,182 |
| Other Operating Expenses | $25,701 | $16,202 | $0 | $0 |
| Operating Expenses | $34,990 | $27,022 | $17,540 | $23,879 |
| Operating Income | -$33,067 | -$28,296 | -$16,054 | -$22,480 |
| % Margin | -1,005.1% | -1,416.2% | -660.9% | -870.6% |
| Other Income/Exp. Net | $1,057 | $24 | -$775 | $372 |
| Pre-Tax Income | -$32,010 | -$28,272 | -$16,829 | -$22,108 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$32,010 | -$28,272 | -$16,829 | -$22,108 |
| % Margin | -972.9% | -1,415% | -692.8% | -856.2% |
| EPS | -3.59 | -3.86 | -2.84 | -9.77 |
| % Growth | 7% | -35.9% | 70.9% | – |
| EPS Diluted | -3.59 | -3.86 | -2.84 | -9.77 |
| Weighted Avg Shares Out | 8,923 | 7,327 | 5,927 | 2,264 |
| Weighted Avg Shares Out Dil | 8,923 | 7,327 | 5,927 | 2,264 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,231 | $943 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $461 | $483 | $493 | $496 |
| EBITDA | -$31,549 | -$27,813 | -$16,336 | -$21,612 |
| % Margin | -958.9% | -1,392% | -672.5% | -837% |